2026年开年以来，国产创新药BD出海延续火热态势，此前石药-阿斯利康（185亿美元）、荣昌-艾伯维 （56亿美元）等重磅合作充分印证国产创新药国际竞争力提升，信达生物本次88.5亿美元大动作为创新 药出海再添一把火！ | 转让方 | 受让方 | 2026年以来中国创新药出海授权交易一览(部分 最高里程碑付款 | 首付款 | | --- | --- | --- | --- | | 石药集团 | 阿斯利康 | 173亿美元 | 12亿美元 | | 荣昌生物 | 艾伯维 | 49.5亿美元 | 6.5亿美元 | | 泽璟制药 | 艾伯维 | 11.35亿美元 | 1亿美元 | | 灰龍ણ | AirNexis | 9.55亿美元 | 1.08亿美元 | | 先声药业 | 勃林格殷格翰 | 10.16亿欧元 | 4200万欧元 | | 宜联生物 | 器联 | 5.7亿美元 | 未单独披露 | | 数据截至2026年1月30日。 | | | | 值得一提的是，港股通创新药板块当前处于阶段低位，港股通创新药ETF（520880）场内价格于上周创 下上市以来新低。低位吸纳创新药便宜筹码，认准港股通创新药ETF（52088 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant growth in License-out transactions from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in early 2026, with the pharmaceutical and biological sector rising by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In early 2026, significant deals were made, including a $12 billion upfront payment from CSPC to AstraZeneca, indicating the growing international competitiveness of Chinese innovative drugs [16][17] Section 2: Performance of the Pharmaceutical Sector - The pharmaceutical sector has shown robust growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, reflecting strong commercialization capabilities [6][23] - The overall industry is moving towards profitability, with companies like Innovent Biologics and Rongchang Biopharma achieving breakeven for the first time [6][23] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the Chinese pharmaceutical sector saw a 0.14% increase, with traditional Chinese medicine leading the gains at 2.56% [7][31] - The medical research outsourcing sector also performed well, increasing by 1.99%, while other subsectors like biological products and vaccines experienced declines [7][31][35]

Market Overview - A-shares experienced volatility on February 6, with the Shanghai Composite Index closing down 0.25% at 4065.58 points, and the ChiNext Index down 0.73% [1] - The overall market turnover decreased to 2.16 trillion yuan, marking a continuous six-day decline in trading volume [1] Sector Performance - The chemical and new energy sectors led the market, while the pharmaceutical sector showed relative resilience. Consumer goods experienced a pullback, and technology continued to be sluggish [1] - The chemical ETF (516020) saw a significant inflow of 199 billion yuan, with a daily gain of 2.37% after reaching a peak increase of 3.45% during the day [2][5][6][8] Chemical Sector Insights - The chemical sector is experiencing a strong upward cycle, driven by increased demand for lithium batteries and key chemical materials [9][10] - Major stocks in the chemical sector, such as Enjie Co., Ltd. and Zhejiang Longsheng, saw significant gains, with some stocks rising over 6% [6][9] Non-Ferrous Metals Sector - The non-ferrous metals sector demonstrated resilience, with the non-ferrous ETF (159876) reversing early losses to close slightly up by 0.18% despite fluctuations in international gold prices [3][11] - Over 100 billion yuan of main funds flowed into the non-ferrous metals sector, indicating strong investor interest [11] Hong Kong Market Dynamics - The Hong Kong market experienced a downward trend, with the Hang Seng Index and Hang Seng Tech Index both closing down over 1% [3] - Despite the overall decline, there was significant buying activity from southbound funds, with purchases reaching 133.7 billion HKD, 249.8 billion HKD, and 148.6 billion HKD over three days [4] Pharmaceutical Sector Developments - The Hong Kong pharmaceutical sector showed signs of recovery, with the innovative drug ETF (520880) rising by 2% during the day, driven by strong earnings forecasts from key companies [15][16] - Notable performers included Innovent Biologics, which projected a revenue increase of approximately 134% by 2025, and several other companies expecting significant profit growth [16][18] Investment Opportunities - Analysts suggest that the chemical sector remains a promising investment opportunity, particularly in leading companies and price recovery products [10][22] - For investors looking to capitalize on the pharmaceutical sector, the innovative drug ETF (520880) and the medical ETF (159137) are recommended for their strong growth potential and coverage of key industry players [21][22]

Group 1: Market Overview - The Hong Kong pharmaceutical sector showed significant recovery on February 6, with innovative drugs experiencing a rebound, particularly the Hong Kong Stock Connect Innovative Drug ETF (520880), which rose by nearly 2% after opening lower [1][8] - Notable stocks included Nocera Health, which surged over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1][8] Group 2: Company Performance - Companies such as Rongchang Biopharmaceutical and CanSino Biologics also reported profitability, with net profit forecasts exceeding 100% year-on-year growth [1][8] - Ark Health announced a profit forecast of 7 to 10 million yuan for 2025, indicating a turnaround from losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3][10] Group 3: ETF Insights - The Hong Kong Stock Connect Innovative Drug ETF (520880) and the Hong Kong Stock Connect Medical ETF (159137) are highlighted as effective investment vehicles, with the former focusing entirely on innovative drug development companies, where the top ten weighted stocks account for over 73% [6][12] - The Hong Kong Stock Connect Medical ETF (159137) has shown strong performance, with 9 out of 10 disclosed component stocks expected to report profits, and several companies projected to double their net profits year-on-year [3][10]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant increases in License-out transaction values from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in the first week of February 2026, with a 0.14% increase, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In 2026, the upfront payment for License-out transactions has already exceeded 39% of the total for 2025, indicating improved quality and competitiveness of Chinese innovative drug pipelines [5][15][16] Section 2: Performance of the Pharmaceutical Sector - The innovative drug sector is experiencing rapid revenue growth, with companies like BeiGene achieving over 36 billion yuan in revenue, showcasing strong commercialization capabilities [6][23] - Major companies such as Innovent Biologics and Rongchang Biopharma have maintained robust growth due to their core products, with some companies achieving profitability for the first time [6][23][24] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the traditional Chinese medicine sector saw the highest increase at 2.56%, while other biopharmaceutical sectors experienced declines [7][31] - The medical research outsourcing sector also performed well, with a 1.99% increase, indicating a positive trend in the pharmaceutical industry overall [7][31][35]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

Market Overview - The Hong Kong stock market opened lower but rebounded slightly, closing down overall. The Hang Seng Index fell by 1.21% to 26,559.95 points, while the Hang Seng Tech Index decreased by 1.11% to 5,346.20 points, and the National Enterprises Index dropped by 0.68% to 9,031.38 points [1] - The Hang Seng Index opened at 26,354.34 points, down 530.90 points, and fluctuated throughout the day, ultimately closing down 325.29 points. The total trading volume exceeded 247.8 billion HKD [1] Capital Flow - The southbound trading under the Stock Connect saw a net inflow of over 14.8 billion HKD on the same day [1] Sector Performance - New consumption, oil and gas stocks generally saw gains, while sectors such as biomedicine, new energy vehicles, coal, and banking experienced mixed results. Conversely, gold, non-ferrous metals, brokerage, real estate, building materials, aviation, and telecommunications stocks mostly declined [1] Individual Stock Movements - Notable individual stock performances included Xiaomi Group up by 0.74%, Meituan down by 2.56%, and SMIC up by 0.22%. Other significant movements included Longi Green Energy up by 4.97%, Hong Kong Exchanges down by 1.64%, and Zijin Mining down by 1.41% [1] - Among the top three stocks by trading volume, Tencent Holdings fell by 1.97% with a turnover exceeding 19.4 billion HKD, Alibaba dropped by 2.88% with over 12 billion HKD in turnover, and AIA Group decreased by 5.54% with a turnover exceeding 4.7 billion HKD [1]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a significant rebound, particularly in innovative drugs, with several companies reporting strong earnings forecasts and positive growth trends [1][8]. Group 1: Innovative Drug Sector - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a rise of nearly 2% after opening lower, indicating strong investor interest [1][8]. - Innovent Biologics (诺诚健华) led the gains with a rise of over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1][8]. - Other companies like Rongchang Biopharmaceutical and CanSino Biologics also reported profitability, with net profit growth exceeding 100% year-on-year [1][8]. Group 2: Medical Sector - The medical sector is also showing positive momentum, with AI healthcare and CXO-related stocks active; Ark Health (方舟健客) led with a 4.71% increase [3][10]. - Ark Health forecasts a profit of 7 to 10 million yuan for 2025, indicating a turnaround from previous losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3][10]. - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to be profitable, with several companies anticipating net profit growth of over 100% [3][10]. Group 3: Market Trends and Investment Opportunities - Despite the positive earnings outlook, the recent performance of the pharmaceutical sector has diverged from these fundamentals, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing four consecutive weeks of declines [5][12]. - The current market conditions may present a favorable opportunity for accumulation in the Hong Kong pharmaceutical sector, particularly through ETFs, which offer higher efficiency and flexibility [5][12]. - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds for a comprehensive exposure to innovative drug companies, with the top ten holdings accounting for over 73% of the portfolio [6][12].